The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients
Détails
ID Serval
serval:BIB_8AACDA39626E
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients
Périodique
Pharmacopsychiatry
ISSN
0176-3679
Statut éditorial
Publié
Date de publication
2002
Peer-reviewed
Oui
Volume
35
Numéro
2
Pages
50-56
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
In this open, 30-day trial, the pharmacokinetics, safety and tolerability of a combination therapy of risperidone (4 or 6 mg/day)and fluoxetine (20mg/day from day 6) were evaluated in 11 psychotic inpatients. CYP2D6 genotyping revealed that 3 and 8 patients were poor metabolizers (PMs) and extensive metabolizers (EMs) of debrisoquine, respectively. The mean (+/- SD) AUC of risperidone increased from 83.1 +/- 46.8 ng.h/ml and 398.3 +/- 33.2 ng.h/ml (monotherapy) to 345.1 +/- 158.0 ng.h/ml (p < 0.05) and 514.0 +/- 144.2 ng.h/ml (p < 0.001) when coadministered with fluoxetine in EMs and PMs, respectively. The AUC of the active moiety (risperidone plus 9-hydroxy-risperidone) increased from 470.0 +/- 170.0 ng.h/ml to 663.0 +/- 243.3 ng.h/ml (p < 0.05)and from 576.3 +/- 19.6 ng.h/ml to 788.0 +/- 89.1 ng.h/ml (ns) in EMs and PMs, respectively. In EMs, the AUC of 9-hydroxy-risperidone remained similar (monotherapy vs. combination therapy: 386.8 +/- 153.0 ng.h/ml vs. 317.7 +/- 125.2 ng.h/ml, ns),whereas it increased in PMs (178.3 +/- 23.5 ng.h/ml vs. 274.0 +/- 55.1 ng.h/ml (p < 0.05)). Ten of the 11 patients showed a clinical improvement (reduction of 20% or more in total PANSS score and 70% on the mean MADRS score compared to baseline). The severity and incidence of extrapyramidal symptoms and adverse events did not significantly increase when fluoxetine was added.
Mots-clé
Adolescent, Adult, Aged, Antidepressive Agents, Second-Generation, Antipsychotic Agents, Area Under Curve, Cytochrome P-450 CYP2D6, Drug Interactions, Female, Fluoxetine, Hemodynamics, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Psychotic Disorders, Risperidone, Switzerland
Pubmed
Web of science
Création de la notice
10/03/2008 11:38
Dernière modification de la notice
20/08/2019 15:49